Neurobiological Mechanisms in Panic Disorder
NCT00103987 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 54
Last updated 2017-07-02
Summary
This study will examine brain and noradrenaline function in panic disorder. Noradrenaline is a brain chemical that is involved in the regulation of emotion, anxiety, sleep, stress hormones such as cortisol, and other body functions that are disturbed in panic disorder.
Healthy normal volunteers and patients with panic disorder between 18 and 60 years of age may be eligible for this study. Candidates are screened with psychiatric and medical histories, a physical examination, blood and urine tests, and an electrocardiogram.
Participants undergo the following tests and procedures:
* Blood draw to obtain DNA for genetic studies of panic disorder - particularly of a gene that helps control noradrenaline activity - and to grow cell lines that can be frozen and used for future research on the disorder.
* Magnetic resonance imaging: MRI uses a magnetic field and radio waves to produce images of body tissues and organs. For this procedure, the subject lies on a table that is moved into the scanner (a narrow cylinder), and wears earplugs to muffle loud knocking and thumping sounds that occur during the scanning process. The procedure lasts about 60 minutes, during which the patient is asked to lie still for 10 to 15 minutes at a time.
* Yohimbine injection with PET scanning: Catheters (plastic tubes) are placed in two veins, one to administer yohimbine, a drug that increases noradrenaline activity in the body for about 60 minutes, and one to draw blood samples. Yohimbine often causes temporary trembling, goosebumps, and clammy palms, and may cause emotions such as elation, anxiety, panic attacks, or depression. During yohimbine administration, subjects undergo positron emission tomography (PET) scanning. PET uses small amounts of a radioactive chemical called \[fluoro-18\]-fluorodeoxyglucose that "labels" active areas of the brain, showing patterns of glucose (sugar) metabolism. For the procedure, the subject lies on the scanner bed, with a special mask fitted to his or her head and attached to the bed to help keep the head still. A brief "transmission" scan is done just before the radioactive tracer is injected in order to calibrate the scanner. After the tracer is injected through the catheter, pictures are taken for about an hour, while the subject lies still on the scanner bed.
* Saline injection with PET scanning: The procedure is the same as that described above, except a saline solution is administered as placebo instead of yohimbine.
Conditions
- Panic Disorder
Sponsors & Collaborators
-
National Institute of Mental Health (NIMH)
lead NIH
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-02-14
- Completion
- 2010-11-12
Countries
- United States
Study Locations
More Related Trials
-
Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ
NCT00088738 ·Status: COMPLETED ·Phase: PHASE1
-
Therapies for Treatment-Resistant Panic Disorder Symptoms
NCT00118417 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Breathing Regulation Training for Individuals With Panic Disorder
NCT00183521 ·Status: COMPLETED ·Phase: NA
-
Neural Effects of Cognitive-behaviour Therapy in Panic Disorder
NCT03251235 ·Status: COMPLETED ·Phase: NA
-
Neurobiology of Generalized Fear-Conditioning & Avoidance in Anxiety Disorders
NCT03033056 ·Status: COMPLETED
-
Effectiveness of Cognitive Behavioral Therapy With Panic Control Treatment for Adolescents With Panic Disorder
NCT00705380 ·Status: COMPLETED ·Phase: PHASE2
-
Panic Disorder and Cardiac Risk
NCT00168506 ·Status: UNKNOWN ·Phase: NA
-
Generalized Anxiety Disorder and Social Anxiety Disorder: Their Impact on the Processing of Information and Learning
NCT00062517 ·Status: COMPLETED
-
Effect of Cognitive-behavior Therapy on Fear Responses to Body Symptoms in Patients With Panic Disorder
NCT04568109 ·Status: COMPLETED ·Phase: NA
-
Intracranial Neurophysiological Signatures of Fear and Anxiety in Humans
NCT05120635 ·Status: RECRUITING ·Phase: NA
-
Disruption of Memory Reconsolidating as a Treatment for Panic Disorder
NCT02631694 ·Status: UNKNOWN ·Phase: PHASE2
-
Expectation of Unpleasant Events in Anxiety Disorders
NCT00055224 ·Status: COMPLETED ·Phase: NA
-
Mechanisms of Panic Disorders Treatment
NCT01323556 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
NCT05232032 ·Status: RECRUITING ·Phase: PHASE2
-
Cognitive vs. Emotional Psychopharmacological Manipulations of Fear vs. Anxiety
NCT02153944 ·Status: COMPLETED ·Phase: PHASE4
-
Augmenting Exposure Therapy With an N-Methyl-D-Aspartate (NMDA) Agonist for Panic Disorder
NCT00131339 ·Status: COMPLETED ·Phase: NA
-
Genetic Abnormalities and Biological Changes of Panic Disorder Patients After Pharmacotherapy
NCT00515996 ·Status: UNKNOWN
-
Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression
NCT00031317 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment of Panic Disorder: Long Term Strategies
NCT00000368 ·Status: COMPLETED ·Phase: PHASE3
-
Identifying Decision Making Parameters in Healthy Volunteers and Anxiety Patients
NCT05092971 ·Status: COMPLETED ·Phase: NA
-
Psychotherapy Outcome and Self-selection Effects in Panic Disorder
NCT01606592 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of HB-1 for Panic Disorder
NCT05071430 ·Status: COMPLETED ·Phase: PHASE2
-
Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders
NCT01333098 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Psychopharmacology of Fear-Potentiated Startle in Humans
NCT00044096 ·Status: COMPLETED
-
Neurobiological Markers of Treatment Response for Anxiety and OCD
NCT05663489 ·Status: RECRUITING